Human ClinicalHuman
Activation of the GH/IGF-1 axis by CJC-1295, a long-acting GHRH analog, results in serum protein profile changes in normal adult subjects
L. Sackmann-Sala, J. Ding, L. A. Frohman, J. J. Kopchick
Study design
Methods snapshot
- Population
- Healthy adults exposed to CJC-1295
- Sample size
- Not indexed
- Intervention
- CJC-1295
- Route
- Not indexed
- Dose reported
- Not indexed
- Frequency
- Not indexed
- Duration
- Not indexed
- Control / placebo
- Not indexed
Outcomes
Primary
- Serum protein profile changes associated with GH/IGF-1-axis activation
Results
Exploratory serum-protein changes were reported after pharmacological activation of the GH/IGF-1 axis.
Interpretation
Provides exploratory downstream biomarker evidence only.
Adverse events
Not indexed in the current record.
Limitations
- Exploratory biomarker study
- Does not establish clinical outcomes
Connected records
Original source
Sempre consulte o artigo original para métodos completos, análises e contexto editorial.
Open PubMed record ↗